Copyright © 2007, European Society of Cardiology
DHEA treatment of pulmonary hypertension: New insights into a complex mechanism
University of Liverpool, School of Clinical Sciences, The Duncan Building, Daulby Street, L69 3GA, Liverpool, UK
dubuis_e@yahoo.fr
Received 1 April 2007; accepted 3 April 2007
| The first 10% of the full text of this article appears below. |
See article by Oka et al. [5] (pages 377–387) in this issue.
Pulmonary arterial hypertension (PAHT) is an implacable killer. Patients developing PAHT present a survival rate of 40% after 36 months [1]. This deadly pathology remains actually an orphan in terms of long-term treatment and affects more than 100,000 patients in the United States and Europe, with an annual incidence estimated at 2 new cases for primary PAHT and 8 new cases for secondary PAHT per million individuals per year.
Pulmonary hypertension is classified into two main categories. The causes of primary PAHT remain largely